Stock Picks
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
10k in revs! A lot better than I thought it would be. Looking forward to seeing this company take off with Brazil revenue next quarter. $MRIB
National retailer announcement this week. (Starting in California) Dan says it's national retailer, other than Costco. Who will it be? Safeway? Walmart? Cvs? Meijer? I can't think of anymore. $MRIB
My California boys are drinking Marani every weekend. They love it!!! I'm expecting the big distribution deal announcement this week. My guess is Safeway! I'd be happy with Walmart too. $MRIB
Dividends for $VGPR shareholders!
MyEcheck stated on FB: When we do show it at the AGM, there will also be the same version for review on our AGM page on our website. $MYEC
Nice! Looks like big Safeway distribution!!! This thing is about to fly. $MRIB
WOW! $MRIB "In the next week or so you will be able to buy Marani at one of the largest liquor distilled spirits retailer in the country." -Dan the Man (Starting in California first)
http://vimeo.com/107876789
A huge surprise on the Brazilian Marani voice over TV spot! A famous Brazillian? $MRIB
VX Gateway is the big mystery here. If there is a big partnership announcement this month, (especially involving international payment processing), then VX gateway will be involved. $MYEC
$AMBS announces huge LymPro revenue guidance: $150 million/year as an RUO - research use only device. Then post CLIA, formal commercialization = $500-Mil. - $1-Bil. market!
Wow, 30,000-plus national retail locations! $MYEC
Buying $MRIB tomorrow at these levels! Shipping to Brazil starts in October, followed by roll out in Mexico. Adding Costco stores. Big distributor in Georgia. This will be the last dip before the explosion.
Big news today! $MYEC doing recurring monthly payment processing. Many businesses will flock to them for lower fees and fraud protection.
Ouch. Another 600,000,000 shares outstanding. $VGPR
HUGE NEWS! "Giact will integrate MyEcheck's electronic services for it's customers, bypassing the ACH system!" $MYEC
Amarantus Enters into Research Collaboration with the Buck Institute for Research on Aging for MANF
San Francisco, CA, Geneva, SWITZERLAND and Novato, CA – August 11, 2014 - Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, announced it has entered into a Research Collaboration with the Buck Institute for Research on Aging for the development of Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) in undisclosed therapeutic indications. MANF is a targeted therapeutic which addresses the underlying programmed cell death (apoptosis) associated with a wide range of devastating human disorders including orphan indications such as Retinitis Pigmentosa.
“We are very pleased to be working with Amarantus on this exciting MANF project,” said Henri Jasper, PhD, professor at the Buck Institute for Research on Aging. “Novel aspects of the biology of MANF are beginning to be uncovered, and I believe working with Amarantus is the best way to coalesce the scientific understanding of MANF and to move the Program forward towards multiple therapeutic applications.”
Under the terms of the agreements, Amarantus has agreed to fund research by Jasper,, and his Buck faculty colleague Deepak Lamba, PhD, and Postdoctoral Fellow Joanna Neves, PhD, to further their scientific insights and generation of intellectual property regarding the therapeutic potential of MANF. In addition, the Company has acquired an exclusive option to license said intellectual property. The Company has also received a right to use certain undisclosed scientific findings for the purpose of regulatory submissions and grant applications to obtain further funding for its programs.
“We are extremely pleased to be adding the Buck Institute for Research on Aging to our expanding consortium of leading academic research institutions focused on furthering the scientific understanding of MANF and its implications for therapeutic development,” said Gerald E. Commissiong, President & CEO of Amarantus. “We were highly impressed with preliminary data generated at the Buck Institute. Given the stellar science from the Jasper and Lamba labs, we are confident that this will be just the beginning of our relationship with the Buck. As we continue our strategy of attracting all relevant MANF intellectual property into the Company on our path towards first-in-man human clinical studies, this agreement greatly adds to our war chest of MANF intellectual property and opens the door to significantly increasing our understanding of this therapeutically relevant, evolutionally conserved protein.”
Dr. Neves has presented several oral presentations on the Buck Institute’s scientific findings regarding MANF at international conferences, including the following:
Drosophila Research Conference, San Diego, March 2014: Hemocyte-mediated repair: promoting retinal repair with MANF.
ARVO annual meeting, Orlando, May 2014: MANF in Retinal Therapies: Improving Regenerative Therapies by Promoting Tissue Repair
Hemocyte-mediated repair: promoting retinal repair with MANF. Joana Neves, Deepak Lamba, Heinrich Jasper. Buck Institute for Research on Aging, Novato, CA.
Regeneration and repair are critical to ensure tissue health throughout life. We are exploring the role of hemocytes in the control of photoreceptor survival and tissue repair in the fly retina. Hemocytes are attracted to the pupal retina and activated by Pvf-1/PvR signaling in response to UV-induced DNA damage, and are required to prevent excessive cell loss. We are now using this system to identify hemocyte-derived factors that can promote tissue repair in the retina, and are testing the conservation of their function in the mammalian retina. We have identified MANF (Mesencephalic Astrocyte-derived Neurotrophic Factor), as a hemocyte derived protein in Drosophila that can promote retinal repair. We find that MANF is induced in hemocytes in response to stress in a Pvf-1/PvR dependent manner, is secreted into the hemolymph, and reduces tissue loss after UV-induced and genetically triggered photoreceptor apoptosis. Moreover, stress-induced MANF results in changes in the hemocyte population that correlate with increased lamellocyte differentiation. Based on these observations, and on the reported cytoprotective function of MANF in the mammalian brain, we hypothesize that MANF has a conserved role in mammals, and that this function can promote integration of transplanted retinal cells into the diseased retina. We find that mouse MANF is induced in microglia and macrophages invading the retina following light damage, and that this correlates with reduced tissue loss. Importantly, intravitreal delivery of MANF recombinant protein is sufficient to limit photoreceptor death following light damage, and promotes beneficial M2 polarization of macrophages/microglia, suggesting that the role of MANF is conserved between flies and mice. Further, we will test the ability of MANF delivery in promoting progenitor cell integration following transplantation. This work will serve as a proof of concept for the use of factors that promote tissue repair as co-adjuvants in stem cell regenerative therapies, and for the use of the fly as a tool to identify such factors.
MANF in Retinal Therapies: Improving Regenerative Therapies by Promoting Tissue Repair. JOANA NEVES, Deepak A. Lamba, Heinrich Jasper. Buck Institute for Research on Aging, Novato, CA.
Purpose: Stem cell based therapies, have been shown to hold real promise in the treatment of degenerative diseases of the retina. However, the efficiency of such strategies is still considerably low. Tissue repair mechanisms are conserved at the organism level and enhance the regenerative process. We hypothesized that promoting
tissue repair may also enhance the efficiency of cell engraftment in the retina. Key components of the retinal repair network have been identified in Drosophila involving interactions between the damaged retina and hemocytes. We have used the Drosophila to identify hemocyte derived factors that can promote tissue repair in the retina and have tested the conservation of their function in the mammalian retina. Our work focused on Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF).
Methods: We have used UV induced retinal damage in flies and light induced retinal damage in mouse as model systems to test the effects of MANF. MANF was overexpressed in flies using the UAS/Gal4 system. In mice, recombinant protein was delivered by intravitreal injection.
Results: We have identified MANF as a hemocyte derived protein in Drosophila that can promote tissue repair in the fly retina, using RNAseq. We show that MANF is expressed in hemocytes of Drosophila larvae, it is secreted to the hemolymph and induced in response to stress in a Pvf-1/PvR dependent manner. Hemocyte specific MANF expression is sufficient to reduce tissue loss after UV and genetically-induced photoreceptor apoptosis. Moreover, stress induced MANF results in changes in the hemocyte population correlating with increased lamellocyte differentiation. We have tested the conservation of the pathway in mammalian retinal repair. As in flies, MANF is induced in microglia/macrophages invading the retina following light damage and this correlates with reduced tissue loss. Importantly, intravitreal delivery of MANF recombinant protein is sufficient to limit cell death following light damage and promotes
alterations in macrophages/microglia.
Conclusions: MANF is a conserved neuroprotective factor in the retina. MANF acts as an immune-modifying factor to limit cell loss following acute damage. This work will serve as a proof of concept to the use of tissue repair promoting factors as co-adjutants in stem cell regenerative therapies.
About Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF)
MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (cell death) in response to injury or disease, via the unfolded protein response o the endoplasmic reticulum. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed. Amarantus is the front-runner and primary holder of intellectual property (IP) around MANF, and is initially focusing on the development of MANF-based protein therapeutics. MANF's current lead indication is Retinitis Pigmentosa, and other applications including Parkinson's disease, and Wolfram’s Syndrome. Additional applications for MANF may include Traumatic Brain Injury (TBI), myocardial infarction, antibiotic-induced ototoxicity and certain other rare orphan diseases currently under evaluation.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready small molecule indicated for Parkinson's Levodopa induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. AMBS also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). Amarantus operations are located at Janssen Labs @QB3 in San Francisco, CA. For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
About the Buck Institute for Research on Aging
The Buck Institute is the U.S.’s first independent research organization devoted to Geroscience – focused on the connection between normal aging and chronic disease. Based in Novato, CA, The Buck is dedicated to extending “Healthspan”, the healthy years of human life and does so utilizing a unique interdisciplinary approach involving laboratories studying the mechanisms of aging and those focused on specific diseases. Buck scientists strive to discover new ways of detecting, preventing and treating age-related diseases such as cancer, Alzheimer’s and Parkinson’s, cardiovascular disease, macular degeneration, osteoporosis, diabetes and stroke. In their collaborative research, they are supported by the most recent developments in genomics, proteomics, bioinformatics and stem cell technologies. For more information: www.thebuck.org
CONTACTS
Amarantus Bioscience Holdings, Inc.
Aimee Boutcher, Investor Relations
408.737.2734 x 101
ir@amarantus.com
Buck Institute for Research on Aging
Kris Rebillot, Director of Communications
415-209-2080
krebillot@buckinstitute.org
$AMBS
New Jason Napodano Blog: Why I'm Still Optimistic On LymPro and Amarantus Bio $AMBS
http://bionapcfa.blogspot.com/2014/08/why-im-still-optimistic-on-lympro-and.html
New $MRIB Tweet: @Maranivodka: Washington State get ready... #marani is on its way!! #maranivodka #seattle #washington
Agreed! Gerald and $AMBS team are happy about these data results. It was exactly what they needed. Here is Warp's email exchange he posted tonight on another board, "I just heard back from Gerald. He will be addressing the market tomorrow, saying there is lots to talk about.
I don't have permission to share his email, so I won't. He did state that today's data thoroughly impressed the biomarker specialists at the conference, and was exactly what big pharma was wanting to see."
I look forward to his words tomorrow. Please, no one ask via PM that I forward his email. It doesn't contain any privileged info. I'm sure everything he remarked on will be shared with all shareholders tomorrow. I want to keep my lines of communication open with our CEO and not jeopardize it by sharing an email I don't have permission to share."
List of MYEC employees on Linkedin! Very solid team and those are just the ones with Linkedin Profiles.
Ed Starrs
Founder & CEO, MyECheck, Inc.
https://www.linkedin.com/profile/view?id=5928577&authType=name&authToken=gFkI&trk=prof-sb-browse_map-name
William "Bill' Delgado
Board Member at MyECheck
Previous has worked for: Global Digital Solutions, Inc., Bronco Communications, LLC, AllStar Telecom - International Fibercom Inc.
https://www.linkedin.com/profile/view?id=38598354&authType=name&authToken=ljpC&trk=prof-sb-browse_map-name
Steve Blandford
CTO at MyECheck Inc.
https://www.linkedin.com/profile/view?id=5294353&authType=name&authToken=KMMK&trk=prof-sb-browse_map-name
Jim Gisler
Director of Merchant Services at MyECheck Inc.
https://www.linkedin.com/profile/view?id=18591726&authType=name&authToken=JeCa&trk=prof-sb-browse_map-name
Erick Iwaishi
Internet Marketing Director / Sr. Web Developer at myEcheck, Inc.
Previous has worked for: Care Innovations, an Intel GE joint venture, SAFE Credit Union, Miyamoto International
https://www.linkedin.com/profile/view?id=191383915&authType=name&authToken=ULiZ&trk=prof-sb-browse_map-name
Nate Wigle
VP Business development, and CMO
Previous has worked for: Paychex (Payroll Provider)
https://www.linkedin.com/profile/view?id=11176181&authType=name&authToken=vSA5&trk=prof-sb-browse_map-name
Brian Phelps
Senior Writer and Chief Content Guy at MyEcheck.com
Previous has worked for: Dataguise, PayPal, Intel Corporation
https://www.linkedin.com/profile/view?id=3291034&authType=name&authToken=NqM-&trk=prof-sb-browse_map-name
That doesn't include Rod Jalunardo: Rod has been a pioneer in the field of digital health information, having developed and implemented many new technologies related to medical data, telemedicine, and financial management systems for health care providers and consumers
http://finance.yahoo.com/news/myecheck-announces-additions-senior-management-174500691.html
Ed said on FB he will be providing some advise on Q2 prior to release. I think we see that soon! $MYEC
I agree. There must be a big partner that we don't know about. Bill Degado is so confident about $MYEC starting the up listing process, that there would have to be something big. I guess audited fins along with this headline would do it..."Myecheck partners with Chase and Bank of America for release of mobile payments apps for MJ-Pay, B2B, P2P, and Gov-Pay!"
Ed answering questions on Facebook now! $MYEC
Simplifile has decided to convert their business all over to $MYEC! Check out Simplifile partners https://simplifile.com/about-simplifile/simplifile-partners/
NEWS RELEASE HERE: $MYEC
MyECheck Leases New Offices, Hires Employees, Engages Patent Litigators
Folsom, California, July 10, 2014 -- MyECheck, Inc. (OTC PK: MYEC), an electronic payment solutions provider and the leader in fully electronic check technology, reports today that they have occupied new corporate offices located in Folsom, CA. The Company has also added a number of full time employees and contractors to facilitate new product launches, and plans to pursue potential patent infringers for licensing revenue.
MyECheck has entered into a 3 year lease agreement for approximately 3200 sq. ft. of class A office space located at 2600 East Bidwell St, suite 140 in Folsom, CA. The new space accommodates 12 to 16 of MyECheck’s personnel, the company is also in the final stages of negotiating a lease for additional space in the same building, suite 190 to accommodate another 12 to 15 employees and contractors.
During the past 3 months, MyECheck has added several new full time employees and several new independent contractors, primarily software developers that have built, and will support the company’s new mobile payment services. Ed Starrs, MyECheck CEO, commented, “our new people are performing extremely well, we have had very ambitious development timelines, and we are now finalizing partner integrations that will enable launch of our new mobile payment services very soon.”
The Company also reports that it has selected a national law firm with a strong track record in major patent litigation cases to represent MyECheck in defense of it’s intellectual property rights. The name of the law firm will be announced once the engagement agreement is finalized.
The audit of the Company’s financial history is proceeding on plan and should be complete before the second quarter reporting deadline of Aug. 15.
About MyECheck: ?MyECheck Inc. is a leading electronic payment technology developer and payment services provider. MyECheck operates under license to US Patent 7,389,913, “Method and Apparatus for Online Check Processing” granted June 2008. The new patented payment method is the fastest, most secure and most cost effective method of processing payments in the US, and it works with the most people, businesses and entities. MyECheck provides comprehensive payment systems for all payment applications including mobile payments and the industry’s most advanced security and fraud control technologies. MyECheck customers include corporations, retailers, governments, payment processors and financial institutions.
Please visit www.myecheck.com
NEWS! $MYEC
Wow! National $MRIB TV commercials!!!
Jul 10, 2014 (eTeligis.com via COMTEX) -- TUSTIN, CA, United States, via eTeligis Inc., 07/10/2014 - - Marani Brands (OTC Pink: MRIB) (PINKSHEETS:MRIB) is proud to announce that Broadcast West of Los Angeles, CA has facilitated the best team to produce Marani's first set of commercials exposing Marani Vodka to the masses. The focus on the commercials will be based on the quality and purity of the award winning Vodka Spirit. Commercials will be produced for national airing focused on key markets first. Broadcast West is a leader in content for the biggest names in the industry from CNN, Discovery Channel, Warner Brothers Pictures, Bloomberg Television, A&E and many others.
New $MYEC twitter post by Brian Phelps: @phelpstek: Good news for #myecheck : Pot Stores to open in Seattle on Tuesday http://t.co/AUgHKgI3PH
And is Marani on this "largest Midwest distributor (of spirits)" radar? I would love to hear US distribution news soon.
Added 21k. Ready for multiple PRs. $MYEC
"Rest assured, we ARE selling!" -Marani Facebook in reference to Costco sales. $MRIB
"We plan to look at patent infringers very soon and decide the appropriate course of action" $MYEC -Ed on FB just now
"We will be starting our marketing beginning in July, it will ramp up over the summer and fall" $MYEC
With the GreenPay acquisition we now have a team of mobile app developers at our disposal! Very smart move by Ed!!! $MYEC
GreenPay LLC is a green payments technology start-up, formed in 2014 by a group of developers from a wide range of backgrounds including gaming applications and mobile payments, to capitalize on emerging payment and banking opportunities in the legal medical and recreational marijuana industry.
We now own 100% of MJ-Pay!!!
GreenPay LLC, is a start-up developer of downloadable mobile payment applications for the legal marijuana industry called MJ-Pay, with marijuana themed apps for Apple and Android devices. MJ-Pay will provide a comprehensive real time fully electronic payment and banking solution that is safe, legal and fully compliant with Federal and State laws.
So now we own GreenPay!!! Does anyone know how many employees we gain? This is a huge addition to our sales force and overall revenues. $MYEC
Amazon launches PayPal competitor. Anyone think this has anything to do with $MYEC?
http://money.cnn.com/2014/06/09/technology/amazon-payments/index.html?hpt=hp_t2